Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer.
Joseph A SparanoRobert J GrayDella F MakowerKathleen I PritchardKathy S AlbainDaniel F HayesCharles E GeyerElizabeth C DeesMatthew P GoetzJohn A OlsonTracy LivelySunil S BadveThomas J SaphnerLynne I WagnerTimothy J WhelanMatthew J EllisSoonmyung PaikWilliam C WoodPeter M RavdinMaccon M KeaneHenry L Gomez MorenoPavan S ReddyTimothy F GogginsIngrid A MayerAdam M BrufskyDeborah L ToppmeyerVirginia G KaklamaniJeffrey L BerenbergJeffrey AbramsGeorge W SledgePublished in: The New England journal of medicine (2018)
Adjuvant endocrine therapy and chemoendocrine therapy had similar efficacy in women with hormone-receptor-positive, HER2-negative, axillary node-negative breast cancer who had a midrange 21-gene recurrence score, although some benefit of chemotherapy was found in some women 50 years of age or younger. (Funded by the National Cancer Institute and others; TAILORx ClinicalTrials.gov number, NCT00310180 .).